| 000 | 01859cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223031038.0 | ||
| 008 | 140910s2014 ua d f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.19.04.M.Sc.2014.Ih.M | ||
| 100 | 0 | _aIhab Abdelrahman Ibrahim Eldessouki | |
| 245 | 1 | 0 |
_aMinimal residual disease assessment in adult AML patients / _cIhab Abdelrahman Ibrahim Eldessouki ; Supervised Nasr Mohamed Ali El lahlobi , Ola Khorshid , Eman kandeel |
| 246 | 1 | 5 | _aدراسة عن الآثار المتبقية الطفيفة فى مرضى اللوكيميا الميلودية الحادة |
| 260 |
_aCairo : _bIhab Abdelrahman Ibrahim Eldessouki , _c2014 |
||
| 300 |
_a155 P. : _bcharts ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Oncology (Medical) | ||
| 520 | _aMinimal residual disease had proven being an interesting new way for stratifying adult AML patients and allowing changing treatment accordingly either through intensifying treatment or going for allogeneic bone marrow transplantation post induction or fewer cycle of consolidation We highly recommend to investigate larger number of patients and keep under close follow up for MRD and other cytogenetic findings post induction and consolidation treatment to be able to be able to introduce MRD as a standard method for adult AML risk stratification | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aAdult | |
| 653 | 4 | _aAML | |
| 653 | 4 | _aMRD | |
| 700 | 0 |
_aEman kandeel , _eSupervisor |
|
| 700 | 0 |
_aNasr Mohamed Ali Ellahlobi , _eSupervisor |
|
| 700 | 0 |
_aOla Khorshid , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aAml _eCataloger |
||
| 905 |
_aNazla _eRevisor |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c47308 _d47308 |
||